Polyacrylate-based delivery system for self-adjuvanting anticancer peptide vaccine

Area of Science:

• Biotechnology
• Immunology
• Oncology

Background:

• Vaccination presents a safer alternative to chemotherapy by leveraging the body's immune system against cancer.
• Peptide vaccines targeting human papillomavirus (HPV)-16 E7 oncoprotein aim to induce cytotoxic T cell responses for HPV-related cancers.
• Current peptide vaccines require adjuvants or delivery systems due to inherent low immunogenicity.

Purpose of the Study:

• To develop novel polymer-peptide conjugates as an efficient self-adjuvanting system for peptide-based therapeutic vaccines.
• To evaluate the efficacy of these conjugates in a preclinical cancer model.

Main Methods:

• Creation of polymer-peptide conjugates designed for self-adjuvanting properties.
• Administration of a single-dose immunization using the developed conjugates in a mouse model with E7-positive TC-1 tumors.
• Assessment of tumor growth reduction and eradication.
• Evaluation of antigen-presenting cell uptake and T cell activation (CD4+ and CD8+).

Main Results:

• The polymer-peptide conjugates demonstrated significant reduction in tumor growth and complete eradication of E7-positive TC-1 tumors in mice after a single immunization.
• The self-adjuvanting conjugates exhibited superior anticancer efficacy compared to antigen formulated with a commercial adjuvant.
• Antigen-presenting cells, including dendritic cells and macrophages, readily took up the conjugates.
• Efficient activation of CD4+ T-helper cells and CD8+ cytotoxic T lymphocytes was observed.

Conclusions:

• The developed polymer-peptide conjugates represent a promising self-adjuvanting platform for peptide-based cancer vaccines.
• This novel approach offers a potent and efficient single-shot immunization strategy against HPV-related cancers.
• The conjugates effectively harness the immune system to combat tumors, outperforming traditional adjuvant formulations.